Sars Cov-2 Virus

Antibodies against the novel coronavirus wane at different rates, lasting for mere days in some individuals, while persisting in others for decades, according to a new study which says COVID-19 severity could be a deciding factor in having longer-lasting protection against reinfection.

Indian Institute of Science claimed on Tuesday that researchers led by Raghavan Varadarajan, Professor at IISc's Molecular Biophysics Unit, are working towards developing effective vaccine strategies against two viruses: SARS-CoV-2 and HIV.

Researchers at the Indian Institute of Technology (IIT), Guwahati have developed methods to detect and prevent the novel coronavirus using bio-interface interactions between the virus and the surface spike protein.

Antibodies against the novel coronavirus wane at different rates, lasting for mere days in some individuals, while persisting in others for decades, according to a new study which says COVID-19 severity could be a deciding factor in having longer-lasting protection against reinfection.

Indian Institute of Science claimed on Tuesday that researchers led by Raghavan Varadarajan, Professor at IISc's Molecular Biophysics Unit, are working towards developing effective vaccine strategies against two viruses: SARS-CoV-2 and HIV.

Researchers at the Indian Institute of Technology (IIT), Guwahati have developed methods to detect and prevent the novel coronavirus using bio-interface interactions between the virus and the surface spike protein.